View Older Stories View More Recent Stories
-
Scotiabank Starts Pfizer (PFE) at Sector Outperform
-
Popular stocks with increasing volume: SOFI PFE SMR
-
Viking Therapeutic (VKTX) PT Raised to $107 at Canaccord Genuity
-
Popular stocks with increasing volume: CRWV AMD OPEN PLTR RIVN PFE SMCI ORCL SOFI IREN
-
FDA Approves Generic Version Of Pfizer's (PFE) Premarin
-
Pfizer amends merger deal with Metsera, raising value to $86.25 per share
-
Novo CEO Says Bid For Metsera Is Higher Than Pfizer's Is Today
-
Novo Nordisk Is Said To Sweeten Bid For Obesity Startup Metsera - Bloomberg
-
Bernstein Reiterates Market Perform Rating on Pfizer (PFE)
-
Pfizer vows to continue Metsera legal fight after court denies restraining order
-
Pfizer Preps Improved Offer In Metsera Bidding War - WSJ
-
Pfizer Denied Temporary Block On Novo Nordisk’s Metsera Bid - Bloomberg
-
Pfizer Drops Demand That Metsera Denounce Novo Bid: Metsera - Bloomberg
-
FTC Says Novo-Metsera Bid Raises Merger Filing Concerns - Bloomberg
-
Pfizer has removed conditions on sale of Arch Venture shares and Metsera public statements from its Metsera bid - Pfizer letter to court
-
Goldman Sachs on Pfizer (PFE): 'Challenging Crosscurrents As Focus Shifts To 2026 Guidance Next Month'
-
Pfizer (PFE) CEO: our bid for Metsera has taken into consideration that prices of GLP-1 will probably start going down - Conference Call
-
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies - FT
-
Metsera declares Novo Nordisk's $10 billion bid superior to Pfizer offer
-
Pfizer raises and narrows full-year earnings guidance
-
Michael Burry buys puts on Nvidia, Palantir
-
Pfizer (PFE) Tops Q3 EPS by 21c, Misses on Revenue; Offers FY25 Guidance
-
Michael Burry's Scion Asset Management Updates 13F
-
Pfizer earnings preview: Leerink trims estimates
-
Metsera responds to Pfizer litigation amid competing acquisition bids
-
Pfizer (PFE) 2.6 calls to 1 put into quarter results
-
Pfizer files second lawsuit against Novo Nordisk over Metsera acquisition
-
Metsera responds to Pfizer litigation, will address claims in court
-
Pfizer sues Metsera directors and Novo Nordisk over merger breach
-
Pfizer gets early FTC clearance for Metsera acquisition
-
Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera
-
Pfizer mulls suing Metsera, Novo Nordisk over topping bid - Semafor
-
Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ
-
Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says Pfizer
-
Pfizer calls Novo Nordisk's Metsera bid reckless and illegal
-
ViiV Healthcare's Dovato matches Biktarvy efficacy with less weight gain
-
Pfizer's TUKYSA shows positive results in breast cancer trial
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE)
-
Pfizer to present research data at IDWeek 2025 conference
-
Guggenheim Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.8% Yield
-
Acting CDC head Jim O’neill: I call on vaccine manufacturers to develop safe monovalent vaccines to replace the combined MMR - X post
-
Wells Fargo sees 'room to run' for Johnson & Johnson, highlights pharma upside
-
Popular stocks with increasing volume: PFE MSTR SMCI INTC PLTR MU NKE AMD SOFI ORCL HOOD COIN
-
Pfizer (PFE) call put ratio 5.7 calls to 1 put with a focus on January 30 and June 35 and 37 calls
-
Trump deal a 'meaningful win' for Pfizer (PFE) - BMO
-
US Pausing Pharma Duties While Negotiations Ongoing - Politico
-
Popular stocks with increasing volume: PFE MSTR SMCI INTC PLTR MU NKE AMD SOFI ORCL HOOD COIN
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
